Biofidelity Awarded £500K Innovate UK Grant to Develop Noninvasive MDx Tools

Dec

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Dec

Featured Webinar

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.

Jan

Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Menu

Biofidelity Awarded £500K Innovate UK Grant to Develop Noninvasive MDx Tools

To read the full story....

Breaking News

Seattle Genetics Presents Positive Tucatinib Phase II Data for HER2-Positive Breast Cancer

Molecular Subgroup May Benefit From Less Toxic CDK4/6 Treatment in ER+ Neoadjuvant Setting

Eli Lilly Opens Phase III Trial for RET Fusion-Positive Non-Small Cell Lung Cancer Drug

Novel HER2 Antibody-Drug Conjugate Shows Promise in Heavily Pretreated Breast Cancer Patients

Benefit Holds Up for Dual Adjuvant HER2 Treatment in Updated Trial Results

Vedanta, Bristol-Myers Squibb to Study Immuno-oncology Combo Therapy for Variety of Cancers

Featured White Papers

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

What's Popular?

Roche Ending Partnership With Syapse

Beat AML Umbrella Trial Demonstrates Feasibility of Rapid Precision Medicine Approach

Eli Lilly Opens Phase III Trial for RET Fusion-Positive Non-Small Cell Lung Cancer Drug

Seattle Genetics Presents Positive Tucatinib Phase II Data for HER2-Positive Breast Cancer

Molecular Subgroup May Benefit From Less Toxic CDK4/6 Treatment in ER+ Neoadjuvant Setting

Sponsorships